You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
來凱醫藥-B(02105.HK):LAE102針對肥胖症治療的I期單劑量遞增研究(SAD研究)所有受試者已完成給藥
格隆匯 12-04 06:25

格隆匯12月4日丨來凱醫藥-B(02105.HK)發佈公吿,LAE102的I期臨牀試驗進展順利。截至本公吿日,該I期單劑量遞增研究(“SAD研究”)中的所有受試者(8個靜脈輸注和皮下注射遞增劑量隊列,總計64位受試者),均已完成給藥,已觀察到靶標結合的早期跡象和預期的藥效生物標誌物變化,以及良好的安全性。該I期臨牀試驗系一項隨機、雙盲、安慰劑對照研究,旨在評估LAE102注射液,分別在健康成年受試者及超重╱肥胖受試者中的安全性、耐受性及藥代動力學。

在完成I期臨牀試驗的單劑量遞增研究後,集團將會按照計劃啟動I期多劑量遞增研究(“MAD研究”),以進一步評估耐受性和療效,加快推動LAE102的臨牀研發及商務進展。集團致力於將這種精準治療帶給那些需要新型治療選擇以實現高質量體重控制的超重和肥胖症患者。

又及,在充滿挑戰的宏觀經濟環境下,實施嚴格謹慎的財務管理乃致勝關鍵。集團已經且將會繼續保持嚴謹的發展戰略,以維持集團健康的財務狀況及穩定的現金流表現,使集團有足夠財務資源支持和加快LAE102的臨牀開發進展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account